260 related articles for article (PubMed ID: 20460421)
1. The diagnosis of GH deficiency in obese patients: a reappraisal with GHRH plus arginine testing after pharmacological blockade of lipolysis.
Scacchi M; Orsini F; Cattaneo A; Grasso A; Filippini B; Pecori Giraldi F; Fatti LM; Moro M; Cavagnini F
Eur J Endocrinol; 2010 Aug; 163(2):201-6. PubMed ID: 20460421
[TBL] [Abstract][Full Text] [Related]
2. Effect of acute pharmacological reduction of plasma free fatty acids on growth hormone (GH) releasing hormone-induced GH secretion in obese adults with and without hypopituitarism.
Cordido F; Fernandez T; Martinez T; Peñalva A; Peinó R; Casanueva FF; Dieguez C
J Clin Endocrinol Metab; 1998 Dec; 83(12):4350-4. PubMed ID: 9851776
[TBL] [Abstract][Full Text] [Related]
3. Comparison between insulin tolerance test, growth hormone (GH)-releasing hormone (GHRH), GHRH plus acipimox and GHRH plus GH-releasing peptide-6 for the diagnosis of adult GH deficiency in normal subjects, obese and hypopituitary patients.
Cordido F; Alvarez-Castro P; Isidro ML; Casanueva FF; Dieguez C
Eur J Endocrinol; 2003 Aug; 149(2):117-22. PubMed ID: 12887288
[TBL] [Abstract][Full Text] [Related]
4. Restoration of growth hormone (GH) response to GH-releasing hormone in elderly and obese subjects by acute pharmacological reduction of plasma free fatty acids.
Pontiroli AE; Manzoni MF; Malighetti ME; Lanzi R
J Clin Endocrinol Metab; 1996 Nov; 81(11):3998-4001. PubMed ID: 8923850
[TBL] [Abstract][Full Text] [Related]
5. The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index.
Corneli G; Di Somma C; Baldelli R; Rovere S; Gasco V; Croce CG; Grottoli S; Maccario M; Colao A; Lombardi G; Ghigo E; Camanni F; Aimaretti G
Eur J Endocrinol; 2005 Aug; 153(2):257-64. PubMed ID: 16061832
[TBL] [Abstract][Full Text] [Related]
6. Unaltered ratio of circulating levels of growth hormone/GH isoforms in adults with Prader-Willi syndrome after GHRH plus arginine administration.
Rigamonti AE; Grugni G; Marazzi N; Bini S; Bidlingmaier M; Sartorio A
Growth Horm IGF Res; 2015 Aug; 25(4):168-73. PubMed ID: 26059749
[TBL] [Abstract][Full Text] [Related]
7. Retesting young adults with childhood-onset growth hormone (GH) deficiency with GH-releasing-hormone-plus-arginine test.
Aimaretti G; Baffoni C; Bellone S; Di Vito L; Corneli G; Arvat E; Benso L; Camanni F; Ghigo E
J Clin Endocrinol Metab; 2000 Oct; 85(10):3693-9. PubMed ID: 11061526
[TBL] [Abstract][Full Text] [Related]
8. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism.
Colao A; Di Somma C; Pivonello R; Loche S; Aimaretti G; Cerbone G; Faggiano A; Corneli G; Ghigo E; Lombardi G
J Clin Endocrinol Metab; 1999 Jun; 84(6):1919-24. PubMed ID: 10372687
[TBL] [Abstract][Full Text] [Related]
9. Acipimox potentiates growth hormone (GH) response to GH-releasing hormone with or without pyridostigmine by lowering serum free fatty acid in normal and obese subjects.
Lee EJ; Nam SY; Kim KR; Lee HC; Cho JH; Nam MS; Song YD; Lim SK; Huh KB
J Clin Endocrinol Metab; 1995 Aug; 80(8):2495-8. PubMed ID: 7629249
[TBL] [Abstract][Full Text] [Related]
10. Elevated insulin levels contribute to the reduced growth hormone (GH) response to GH-releasing hormone in obese subjects.
Lanzi R; Luzi L; Caumo A; Andreotti AC; Manzoni MF; Malighetti ME; Sereni LP; Pontiroli AE
Metabolism; 1999 Sep; 48(9):1152-6. PubMed ID: 10484056
[TBL] [Abstract][Full Text] [Related]
11. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression.
Cordido F; Peino R; Peñalva A; Alvarez CV; Casanueva FF; Dieguez C
J Clin Endocrinol Metab; 1996 Mar; 81(3):914-8. PubMed ID: 8772550
[TBL] [Abstract][Full Text] [Related]
12. Comparison between insulin-induced hypoglycemia and growth hormone (GH)-releasing hormone + arginine as provocative tests for the diagnosis of GH deficiency in adults.
Aimaretti G; Corneli G; Razzore P; Bellone S; Baffoni C; Arvat E; Camanni F; Ghigo E
J Clin Endocrinol Metab; 1998 May; 83(5):1615-8. PubMed ID: 9589665
[TBL] [Abstract][Full Text] [Related]
13. Long-term administration of acipimox potentiates growth hormone response to growth hormone-releasing hormone by decreasing serum free fatty acid in obesity.
Nam SY; Lee ; Kim KR; Lee HC; Nam MS; Cho JH; Huh KB
Metabolism; 1996 May; 45(5):594-7. PubMed ID: 8622602
[TBL] [Abstract][Full Text] [Related]
14. GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism.
Procopio M; Maccario M; Savio P; Valetto MR; Aimaretti G; Grottoli S; Oleandri SE; Baffoni C; Tassone F; Arvat E; Camanni F; Ghigo E
Panminerva Med; 1998 Mar; 40(1):13-7. PubMed ID: 9573747
[TBL] [Abstract][Full Text] [Related]
15. The growth hormone (GH) response to the arginine plus GH-releasing hormone test is correlated to the severity of lipid profile abnormalities in adult patients with GH deficiency.
Colao A; Cerbone G; Pivonello R; Aimaretti G; Loche S; Di Somma C; Faggiano A; Corneli G; Ghigo E; Lombardi G
J Clin Endocrinol Metab; 1999 Apr; 84(4):1277-82. PubMed ID: 10199767
[TBL] [Abstract][Full Text] [Related]
16. Effects of 36 hour fasting on GH/IGF-I axis and metabolic parameters in patients with simple obesity. Comparison with normal subjects and hypopituitary patients with severe GH deficiency.
Maccario M; Aimaretti G; Grottoli S; Gauna C; Tassone F; Corneli G; Rossetto R; Wu Z; Strasburger CJ; Ghigo E
Int J Obes Relat Metab Disord; 2001 Aug; 25(8):1233-9. PubMed ID: 11477509
[TBL] [Abstract][Full Text] [Related]
17. Relationship between the morphological evaluation of the pituitary and the growth hormone (GH) response to GH-releasing hormone Plus arginine in children and adults with congenital hypopituitarism.
Maghnie M; Salati B; Bianchi S; Rallo M; Tinelli C; Autelli M; Aimaretti G; Ghigo E
J Clin Endocrinol Metab; 2001 Apr; 86(4):1574-9. PubMed ID: 11297586
[TBL] [Abstract][Full Text] [Related]
18. Effects of acipimox, an antilipolytic drug, on the growth hormone (GH) response to GH-releasing hormone alone or combined with arginine in obesity.
Maccario M; Procopio M; Grottoli S; Oleandri SE; Boffano GM; Taliano M; Camanni F; Ghigo E
Metabolism; 1996 Mar; 45(3):342-6. PubMed ID: 8606641
[TBL] [Abstract][Full Text] [Related]
19. Effect of acipimox, a lipid lowering drug, on growth hormone (GH) response to GH-releasing hormone in normal subjects.
Pontiroli AE; Lanzi R; Monti LD; Pozza G
J Endocrinol Invest; 1990 Jun; 13(6):539-42. PubMed ID: 2258583
[TBL] [Abstract][Full Text] [Related]
20. Acute pharmacological reduction of plasma free fatty acids enhances the growth hormone (GH)-releasing hormone-mediated GH secretion in patients with Cushing's syndrome.
Leal-Cerro A; Jimenez LM; Astorga R; Fernandez-Lopez I; Dieguez C; Casanueva FF
J Clin Endocrinol Metab; 1997 Sep; 82(9):3165-8. PubMed ID: 9284763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
